Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of HCP2202 (Aspirin/Rabeprazole) FDC vs Co-administration in Healthy Volunteers
NCT05548543Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Oct 2022
- Primary completion
- Dec 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of aspirin and rabeprazole in cardiovascular diseases (CVD) and gastric ulcer (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Area Under the Curve from time 0 to last measurable concentration and Maximum Plasma Concentration. Started Oct 2022; status: completed.
02
Drugs
aspirinrabeprazole
03
Conditions
cardiovascular diseases (CVD)gastric ulcer
Beyond the preview
Go deeper on NCT05548543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05548543.